Supernus Pharmaceuticals SG&A Expenses 2011-2024 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Supernus Pharmaceuticals SG&A Expenses 2011-2024 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Supernus Pharmaceuticals sg&a expenses from 2011 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
Dr Reddy's Laboratories (RDY)	$12.6B
BridgeBio Pharma (BBIO)	$5.1B
Bausch Health Cos (BHC)	$3.4B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Taysha Gene Therapies (TSHA)	$307M
Personalis (PSNL)	$241M
Assembly Biosciences (ASMB)	$106M
Sol-Gel Technologies (SLGL)	$16M
Evoke Pharma (EVOK)	$5M
Teligent (TLGT)	$0M